Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by gojotv!on Apr 06, 2021 7:13pm
251 Views
Post# 32946490

A short math lesson...

A short math lesson...Bashers keep whinging about the "3000 patients" we've acquired.
Hello?
The 3000 patients are not our market.
Our market is all the people you have to test to get 3000 patients.
With maybe up to 2% having actual cancer, you do the math!
Remember, this is a pre-symptomatictest.
Now do you get why the potential here is amazing?
And Health Clinics Ltd. has a stellar reputation for professionalism in oncology. They're going to get ALL the references from doctors in the region.
Those 51 employees will be kept very, very busy.
If they produce profits of just $20,000/head in the next quarter, that's $2.5M. But at the rate they're charging for Aristotle, profits will be much, much higher, IMHO.
Don't regret your "buys" over slander, bullying, and other signs of market churn.
Those who can add and subtract want your shares.


<< Previous
Bullboard Posts
Next >>